Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Ensysce Biosciences, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +16 vs. Q2 2021
- Shares held
- 3.16M
- +3.16M vs. Q2 2021
- Total value
- $9.56M
- +$9.56M vs. Q2 2021
- New holders
- 16
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 64 | $0 | 0.00% | +64 | New |
| Wolverine Asset Management LLC | 2,791 | $8.00K | 0.00% | +2,791 | New |
| Morgan Stanley | 3,269 | $10.0K | 0.00% | +3,269 | New |
| Covington Capital Management | 4,800 | $15.0K | 0.00% | +4,800 | New |
| Tower Research Capital LLC (TRC) | 10,593 | $32.0K | 0.00% | +10,593 | New |
| Two Sigma Securities, LLC | 11,228 | $34.0K | 0.01% | +11,228 | New |
| Jane Street Group, LLC | 12,553 | $38.0K | 0.00% | +12,553 | New |
| Cresset Asset Management, LLC | 13,717 | $42.0K | 0.00% | +13,717 | New |
| Evergreen Capital Management LLC | 14,028 | $43.0K | 0.00% | +14,028 | New |
| Virtu Financial LLC | 25,807 | $78.0K | 0.01% | +25,807 | New |
| FNY Investment Advisers, LLC | 34,113 | $103.0K | 0.05% | +34,113 | New |
| Millennium Management LLC | 38,065 | $115.0K | 0.00% | +38,065 | New |
| Geode Capital Management, LLC | 54,930 | $166.0K | 0.00% | +54,930 | New |
| Founders Fund Ill Management, LLC | 143,575 | $435.0K | 100.00% | +143,575 | New |
| Stifel Financial Corp | 323,342 | $980.0K | 0.00% | +323,342 | New |
| HG Vora Capital Management, LLC | 2,462,500 | $7.46M | 0.28% | +2,462,500 | New |